23andMe Board Members Resign En Masse Amid Takeover Stalemate
All independent directors at 23andMe abruptly resign after losing faith in CEO Anne Wojcicki's plan to take the company private. The mass departure drops the genomics firm's market cap to a mere $173 million.
All independent board members at 23andMe abruptly resign, signaling a major collapse in confidence for the personal genetics company. The mass departure follows CEO Anne Wojcicki's failed attempt to take the 18-year-old company private, a move the board previously rejected in July. These directors lose patience because Wojcicki holds concentrated voting power, making it impossible for them to influence the company's direction.
The company's dramatic downfall stems from fading consumer interest in DNA kits and a massive data breach last year that exposes the ancestry information of 6.9 million users. Once valued at $3.5 billion when it went public in 2021, 23andMe now closes the trading day with a market capitalization of just $173 million. The departing board features high-profile figures like Sequoia Capital's Roelof Botha and YouTube CEO Neal Mohan.
This sudden loss of star board members almost certainly drives the company's stock down even further as investors react to the sudden governance crisis. Legal experts suggest that a shareholder lawsuit is highly likely given the extreme drop in value and the contentious nature of Wojcicki's takeover attempts. The future of 23andMe remains deeply uncertain as the company navigates this severe leadership vacuum.